flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
flanders.bio joins forces with FIT to support the internationalisation of Flanders’ economy
It’s official: flanders.bio has reached a structural collaboration agreement with Flanders Investment & Trade (FIT), Flanders’ agency for international enterprise. The agreement was signed today by Henk Joos, Managing Director at flanders.bio and Claire Tillekaerts, CEO at FIT, during an official ceremony at the Hotel Errera in Brussels. Flanders’ Minister-President Geert Bourgeois also attended the ceremony, formally sealing the reinforced collaboration. This partnership is embedded within ‘Vlaanderen versnelt!’ (‘Flanders accelerates!’), Flanders’ internationalization strategy.
Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Consonance CapMan GP LLC on 11 October 2017.
Ablynx establishes subsidiary in the USA and appoints a general manager
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the establishment of Ablynx, Inc., its subsidiary in the USA, and the appointment of Mr Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America. Mr Daniel (Dan) Schneider will be based in a US office, to be located on the East Coast. Caplacizumab is the Company's wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
Mithra Announces Completion of Recruitment in Donesta® Phase II Study
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the completion of recruitment in the E4 Relief Phase II study of Donesta®, Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4) for Vasomotor Menopausal Symptoms (VMS) relief. Top-line data, based on 12-weeks of treatment, remain on track to be reported late in the first quarter of 2018.
Scientists pinpoint surprising origin of melanoma
Led by Jean-Christophe Marine (VIB-KU Leuven), a team of researchers has tracked down the cellular origin of cutaneous melanoma, the deadliest form of skin cancer. The team was surprised to observe that these very aggressive tumors arise from mature, pigment-producing cells called melanocytes. As melanoma develops, these cells are eventually reprogrammed, lose their differentiated features and become invasive, migratory cancer cells. This knowledge is vital to understand how these melanoma lesions are formed, facilitate their early detection and develop preventive treatment avenues. The results of the study are published in the academic journal Cell Stem Cell.